Menu
Share this

BioDuro Opens State-of-the-Art Discovery Lab in Shanghai

New facility offers customized portfolio of services to meet
expanding client demand

15 May 2013

RSS

WILMINGTON, N.C. (May 15, 2013) – BioDuro, A PPD® Company, today announced it has opened a new state-of-the-art laboratory in Shanghai, strengthening its ability to provide biopharmaceutical clients an extensive range of customized drug discovery services in Asia Pacific. The new lab also enables the company to better support the business needs of its clients by increasing efficiency during discovery and development, and providing greater consistency among the stages of development. In addition, the location of the lab in the Waigaoqiao Free Trade Zone and its proximity to local and multinational pharmaceutical and biotechnology companies in Shanghai will foster their working relationship with BioDuro.

The 72,000-square-foot lab, accompanied by 20,000 square feet of office space, offers integrated drug metabolism and pharmacokinetic (DMPK), bioanalytical, chemistry, discovery biology and oncology pharmacology services. And, because BioDuro is part of the PPD organization, clients also are able to take advantage of a complete menu of clinical research services, as well as an extensive library of assays for testing.

“As a fully integrated life science research service provider, BioDuro has an experienced team of researchers and scientists with expertise in a wide range of drug discovery services,” said Jasmine Cui, Ph.D., general manager and chief scientific officer of BioDuro. “This new lab will allow us to meet the business needs of our clients more effectively by streamlining the discovery and development process, and continuing to enhance continuity and smooth transitions throughout the stages of development. For example, after a compound goes into Phase 0, the PPD organization can offer full clinical research services to develop the compound through post approval.”

BioDuro also has a state-of-the-art, 110,000-square-foot laboratory in Beijing. Through the two operations, BioDuro provides fully integrated, comprehensive drug discovery services covering development from target identification to preclinical/Phase 0.

Contacts
Media:
Randy Buckwalter
+1 919 456 4425
randy.buckwalter@ppdi.com

Investors:
Luke Heagle
+1 910 558 7585
luke.heagle@ppdi.com

About BioDuro
BioDuro, acquired by PPD in 2009, is a leading drug discovery services company. It provides high-quality, integrated preclinical research and development services to biopharmaceutical clients, ranging from medicinal chemistry, discovery biology, pharmacology, DMPK and biologics. For more information, visit www.bioduro.com.

About PPD
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about BioDuro’s new lab in Shanghai, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: risks associated with and dependence on strategic relationships; rapid technological advances that make our services less competitive; competition in the outsourcing industry; compliance with drug development regulations; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; the ability to control SG&A spending; risks associated with acquisitions and investments; the ability to attract, integrate and retain key personnel; and changes in the regulation of the drug development process. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD's estimates or views as of any date subsequent to the date hereof.

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
PPD
Tel: +1 919 456 4425

Elizabeth Humphrey Corporate Communications Manager
PPD
Tel: +1 910 558 6096

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.